Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 14 h ago

Jade Biosciences, Inc.: Paradigm Biocapital Advisors LP amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Paradigm Biocapital Advisors LP amended its Schedule 13G filing for Jade Biosciences, Inc., updating its beneficial ownership disclosure with the SEC under accession number 0001104659-26-128317. The amendment signals a change in the investment firm's reported position in the biotechnology company, though the filing did not disclose the size of the stake or the direction of the change. Schedule 13G amendments are typically filed by passive investors when their ownership crosses certain thresholds or when previously reported holdings change materially. Investors will watch for further 13G or 13D filings to gauge whether Paradigm's position continues to shift.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Jade Biosciences, Inc., Paradigm Biocapital Advisors LP